EGFR and esophageal squamous cell carcinoma: The EGFR tyrosine kinase inhibitor (TKI) helps disrupt cell growth pathways and makes cells more sensitive to RT.14,15 Icotinib, an oral EGFR TKI, has been reported to markedly inhibit the proliferation of the human epidermoid squamous carcinoma A431 cell line with a high level of EGFR.16 Wang et al17 have evaluated the feasibility of icotinib in patients with advanced ESCC with EGFR overexpression.